Dennis (Denny) Ausiello, MD is the Director of the Center for Assessment Technology and Continuous Health (CATCH), a program he founded as a joint effort between Massachusetts General Hospital and Massachusetts Institute of Technology (MIT) physicians, scientists and engineers to provide real-time measurement and analysis of the human phenotype in wellness and disease.
He previously served as Chief of Medicine at Mass General from 1996 until his retirement in 2013. In this role, he led one of the strongest departments of medicine in the country. He is a nationally recognized leader in academic medicine, having been elected to the Institute of Medicine of the National Academy of Science (1999) and the American Academy of Arts and Sciences (2003). He has written for many publications, including the New York Times and the Wall Street Journal, on various health subjects including human genetics, clinical trials, and the relationship between the academy and industry.
As an internationally recognized scientist, with specific expertise in epithelial and membrane biology, ion and water channel regulation and signal transduction, Denny has served as a council member of the National Institute of Diabetes, the Digestive and Kidney Diseases Advisory Council and the National Advisory Council on Aging. He served on the Board of Directors of the Broad Institute, an independent partnership of Harvard and MIT faculty working in human genetics, as well as the Board of Directors of the nonprofit organization, Research!America, the leading advocate group for investment in biomedical research in the United States.
Understanding the need for partnerships between the academy and industry, he currently serves as the Lead Director on the Board of Directors of Pfizer Pharmaceuticals, as well as on the Board of microbiome company Seres Health; TARIS, a drug-delivery company; and Alnylam, an iRNA company. He also serves as an advisor to various biotech companies and venture capital companies working in the biotech and device area. Denny is also a consultant for Verily (formerly Google Life Sciences). He holds a BA from Harvard College and an MD from the University of Pennsylvania.